Contemporary breast cancer outcomes in northern Thailand: insights from an enhanced clinical registry

Background Fragmented referral pathways, incomplete clinical data, and unequal access to modern therapies challenge breast cancer care in many resource-constrained settings. The Chiang Mai Cancer Registry (CMCR) was expanded into a comprehensive clinical registry within the Suandok Breast Cancer Network (SBCN), a regional breast cancer care network in Northern Thailand. Methods We conducted a retrospective cohort study of patients diagnosed with invasive breast cancer within the SBCN between January 2016 and December 2020. Clinical, pathological, and treatment data, including molecular subtypes, surgery, systemic therapy, and radiotherapy, were extracted from electronic medical records. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Results A total of 2,417 patients were included. HR and HER2 status were available in 94.3% of cases, compared with 79.6% in our earlier cohorts. The most common subtype was HR+/HER2− (56.6%), followed by triple-negative breast cancer (14.5%), HR−/HER2+ (13.3%), and HR+/HER2+ (9.9%). Among 564 HER2-positive patients, 59.8% received adjuvant trastuzumab. At a median follow-up of 80.1 months, survival rates differed significantly by subtype. HR+/HER2− patients had the most favorable outcomes (5-year DFS 80.6%, OS 82.0%), whereas triple-negative breast cancer (TNBC) patients had the poorest outcomes (DFS 69.1%, OS 70.5%). Among HER2-positive patients, trastuzumab use was associated with improved DFS (80.4% vs. 65.9%). Conclusions A comprehensive clinical registry improved data completeness and enabled robust evaluation of treatment patterns and outcomes. Increased access to HER2-targeted therapy and favorable survival outcomes highlight continued progress in coordinated breast cancer care within a regional healthcare network.

Authors

Institutions

Publication Details

Journal
Frontiers in Epidemiology
Published
2026-11-18
DOI
https://doi.org/10.3389/fepid.2026.1918223
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Contemporary breast cancer outcomes in northern Thailand: insights from an enhanced clinical registry

Patumrat Sripan, Wimrak Onchan, Narate Waisri, Chagkrit Ditsatham et al.
3 links
Frontiers in Epidemiology
Breast Cancer Treatment Studies
article

Contemporary breast cancer outcomes in northern Thailand: insights from an enhanced clinical registry

Patumrat Sripan, Wimrak Onchan, Narate Waisri, Chagkrit Ditsatham, Phanchaporn Wongmaneerung, Kirati Watcharachan, Puttachart Maneesai, Chirapong Hanpragopsuk, Imjai Chitapanarux, Areewan Somwangprasert, Chaiyut Charoentum, Chularat Duangkaew, Kunlanit Suesatsakun, Jitnarong Karnmanee, Kunsuda Kittidacha
article en

Abstract

Background Fragmented referral pathways, incomplete clinical data, and unequal access to modern therapies challenge breast cancer care in many resource-constrained settings. The Chiang Mai Cancer Registry (CMCR) was expanded into a comprehensive clinical registry within the Suandok Breast Cancer Network (SBCN), a regional breast cancer care network in Northern Thailand. Methods We conducted a retrospective cohort study of patients diagnosed with invasive breast cancer within the SBCN between January 2016 and December 2020. Clinical, pathological, and treatment data, including molecular subtypes, surgery, systemic therapy, and radiotherapy, were extracted from electronic medical records. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Results A total of 2,417 patients were included. HR and HER2 status were available in 94.3% of cases, compared with 79.6% in our earlier cohorts. The most common subtype was HR+/HER2− (56.6%), followed by triple-negative breast cancer (14.5%), HR−/HER2+ (13.3%), and HR+/HER2+ (9.9%). Among 564 HER2-positive patients, 59.8% received adjuvant trastuzumab. At a median follow-up of 80.1 months, survival rates differed significantly by subtype. HR+/HER2− patients had the most favorable outcomes (5-year DFS 80.6%, OS 82.0%), whereas triple-negative breast cancer (TNBC) patients had the poorest outcomes (DFS 69.1%, OS 70.5%). Among HER2-positive patients, trastuzumab use was associated with improved DFS (80.4% vs. 65.9%). Conclusions A comprehensive clinical registry improved data completeness and enabled robust evaluation of treatment patterns and outcomes. Increased access to HER2-targeted therapy and favorable survival outcomes highlight continued progress in coordinated breast cancer care within a regional healthcare network.

Frontiers in EpidemiologyVol. 6
Maharaj Nakorn Chiang Mai Hospital (TH), Chiang Mai University (TH)
Good health and well-being, Reduced inequalities
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon